Hi there,
I am writing to let you know that your 60% MarketBeat discount offer is set to expire in less than 12 hours.
More than one hundred of your fellow MarketBeat newsletter subscribers have upgraded to MarketBeat All Access in the last week (and they have gotten a great deal on their annual membership). Unfortunately, you haven't taken action yet.
We are making MarketBeat All Access available for 60% off (just $99 for the year) for anyone that registers by 11:59 PM Pacific Time. That's a savings of $150.00 on your annual subscription.
Click Here to Upgrade Your Account to MarketBeat All Access
If you aren't completely satisfied with your MarketBeat All Access membership, just send a note to our South Dakota-based customer support team at contact@analystratings.net. You are eligible for a full refund within your first 30 days of membership and we process all refunds within one business day.
Why Upgrade to MarketBeat All Access?
- Access Award-Winning Research Tools - MarketBeat All Access offers a full suite of modern stock research and portfolio monitoring tools backed by comprehensive financial datasets that you can't get anywhere else. MarketBeat tracks more than two million market events and news stories each year, creating an unrivaled ability to provide accurate, complete, and up-to-the-minute financial information.
- Cut Through the Noise - Equities research analysts issue more than 175,000 distinct "Buy" and "Sell" recommendations each year. After tracking the ROI of following analyst recommendations for nearly a decade, we know which analysts you should pay attention to and which you can safely ignore. With your All Access subscription, you'll get access to our list of top-rated and most-accurate brokers as well as their most recent "Buy" and "Sell" recommendations.
- Real-Time Data for Timely Trades - You will be among the first to receive your daily newsletter and instant email and SMS alerts for important market events. You won't need to scour through dozens of different websites to find news relevant to your stocks. Use MarketBeat All Access to get ratings, earnings, dividends, insider trades, and headlines delivered to your inbox automatically, every day.
Save 60% on MarketBeat All Access
Matthew Paulson
MarketBeat
P.S. This offer is only available through 11:59 PM Pacific tonight. Take action now!
Register Here for MarketBeat All Access
Short Squeeze Alert—Moderna Stock Surges on New Strategy
Author: Chris Markoch. Article Published: 7/1/2026.
Key Points
- Moderna shares rose nearly 20% after Science Day, but the gain is partly attributed to a short squeeze, not fundamentals alone.
- Moderna's pipeline spans three horizons targeting cancer and rare diseases, though Horizons 2 and 3 will not generate revenue until after 2028.
- With MRNA trading near double its consensus price target of $37, analysts suggest waiting for a better entry point before adding exposure.
- Special Report: SpaceX is offering you shares. Don't take them.
Shares of Moderna (NASDAQ: MRNA) are acting as if it were 2020 again. The stock is up nearly 20% since the company’s Science Day event.
At that event, Moderna outlined its strategy for using mRNA to combat cancer and rare diseases. It’s a move beyond vaccines, and investors seem to like it.
Free today, paid tomorrow (Ad)
Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade.
Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires.
Download your free copy of Your First Trade Playbook todayLooks, however, can be deceiving. Before the event, MRNA had short interest of over 16.5%, which required more than 10 days for short sellers to cover their positions.
The result was a classic short squeeze that has pushed the stock to nearly double its consensus price target of around $37 as of June 30.
However, the price move by itself isn’t disqualifying. The real promise has always been in the expansion of mRNA as a treatment for disease. That leaves investors with a decision ahead of the company’s Q2 2026 earnings report, scheduled for July 30.
Why mRNA Still Matters
The promise of mRNA is that it changes how medicine is made. Traditional drugs are manufactured in factories and then injected into the body. mRNA medicines work differently. They deliver genetic instructions, and the body’s own cells produce the protein needed to treat the disease.
That matters for two reasons. The same platform can be reprogrammed for different diseases by changing only the instructions, and that flexibility could make drug development faster and more efficient over time.
COVID-19 vaccines proved the platform works in infectious disease. The question Moderna is now trying to answer is whether the same approach can deliver meaningful results for cancer, autoimmune diseases, and rare diseases.
If the answer is yes, the platform becomes far more valuable than its vaccine franchise alone. That’s the long-term story driving the recent move.
3 Horizons, 1 Long Runway
At Science Day, Moderna organized its business into three "Horizons" that map how the platform scales over time.
Horizon 1 is Moderna’s commercial engine. It includes four approved vaccines (Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX), the investigational intismeran autogene cancer therapy, and a rare disease franchise led by a propionic acidemia treatment. This accounts for the bulk of the company’s current revenue.
Horizon 2 is the next wave. It includes T-cell engagers targeting multiple myeloma and ovarian cancer, cancer antigen therapies for solid tumors and Lynch syndrome, and a multiple sclerosis therapeutic linked to the Epstein-Barr virus. Most are in Phase 1 or Phase 2 trials. The earliest meaningful readout is mRNA-1195 for multiple sclerosis, which is expected in the second half of 2026.
Horizon 3 is the long-term bet. The headline asset is mRNA-6007, an in vivo CAR-T therapy aimed at lupus. Moderna expects it to enter human trials by the end of 2027.
That’s a lot of potential. However, neither Horizon 2 nor Horizon 3 will generate revenue until after 2028. Phase 1 and Phase 2 readouts are clinical milestones, not commercial ones. The path from trial to approval to launch takes years.
Why Caution Is Warranted
On June 26, the day after Moderna’s Science Day event, Piper Sandler reiterated its Overweight rating on MRNA and raised its price target to $77 from $69. Even at the prior target, Piper Sandler was already one of the most bullish analysts.
It’s important to note, however, that the new price target doesn’t leave much upside for MRNA after its recent gains. Analysts may be holding off on issuing opinions until the company’s earnings report, especially since there won’t be any revenue or earnings from these new initiatives for several years.
That puts the burden on Horizon 1. The four approved vaccines, the intismeran Phase 3 program, and disciplined cash management have to fund the pipeline long enough for the platform story to pay off.
That’s why long-term investors who aren’t in the stock should wait for a better entry point. It’s also a reason for current shareholders to take some risk off the table.
Where the Squeeze Logically Gives Back
The most likely first pullback level is $60. It's a round-number psychological level and represents a healthy give-back of about half the move off the mid-June breakout. Pullbacks of that size are normal after a sharp rally; they are typical profit-taking and leave the bullish structure intact. Anyone trimming into the squeeze would look to add back near this level.
The deeper, higher-conviction support is $55. That was the top of the April-to-June trading range, and the launch point of the Science Day breakout candle. Prior resistance becomes new support, and this is where the squeeze froth fully resets without breaking the thesis.
The line in the sand is $52, where the 50-day SMA sits at $51.83. A close below that level would mean the breakout has failed, and the stock has fallen back into the range it traded in before Science Day. At that point, the platform re-rate needs a fresh catalyst, such as the July 30 earnings report, to reassert itself.
Apple Just Handed These 4 Memory Stocks Their Best News of the Year
Author: Bridget Bennett. Article Published: 6/28/2026.
Key Points
- Analyst Louis Navellier ranks Micron as the top beneficiary of a structural memory shortage, citing a two-to-three-year order backlog and expanding margins.
- Seagate, Western Digital, and Sandisk also score well on Navellier's fundamental model, with all four stocks positioned to benefit from ongoing AI-driven data center demand.
- Navellier favors buying into pullbacks of 3 to 4 percent rather than chasing strength, and views large existing gains as confirmation of fundamentals, not a reason to sell.
- Special Report: SpaceX is offering you shares. Don't take them.
When Apple (NASDAQ: AAPL) says it may have to raise prices because memory costs are rising, the market pays attention. For investors already holding Micron Technology (NASDAQ: MU), Seagate Technology Holdings (NASDAQ: STX), Western Digital Corporation (NASDAQ: WDC), and Sandisk Corporation (NASDAQ: SNDK), that warning isn't a red flag—it's confirmation of pricing power.
Growth Investor's Louis Navellier sees all four names as direct beneficiaries of the same structural shortage, with one clear leader at the top of the stack.
When Pricing Power Meets a 2-Year Backlog
Free today, paid tomorrow (Ad)
Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade.
Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires.
Download your free copy of Your First Trade Playbook todayThe setup for Micron is straightforward: data centers want the fastest memory chips available, Micron makes them, and demand is running well ahead of supply. That's why analysts—who have historically lagged on this stock—keep revising estimates upward, and why the order backlog tells a more compelling story than the revenue line alone.
Navellier calls Micron something close to a monopoly in the data center memory segment. Samsung (OTCMKTS: SSNLF) competes on volume, but for hyperscalers building out AI infrastructure, Micron's high-bandwidth memory is the preferred choice.
That preference translates directly into operating margins. When you have pricing power in a supply-constrained market, margins expand—and Micron's have.
He ranks Micron at the top of his eight-factor fundamental model, which weighs sales growth, margin expansion, earnings stability, analyst revisions, and surprise history. Recent upward revisions across the analyst community, he notes, are a reliable signal of what's coming. Micron's last earnings report blew past expectations, and Navellier sees that pattern continuing—particularly given that analysts in this space are notoriously conservative, penalized more for overestimating than for being late.
The order backlog, extending roughly two to three years out and driven by data center construction, is why he isn't treating this as a late-cycle trade. More than half of U.S. construction activity is currently tied to data center builds, and whoever has the chips has the leverage.
The Reliability Play in an Unreliable Market
Not every data center storage decision comes down to the fastest chip. Reliability matters enormously—downtime in a hyperscale facility is catastrophic—and that's where Seagate has built its reputation over decades of enterprise deployments.
Navellier calls Seagate his favorite solid-state name in the group. Its data center business is accelerating as the transition from spinning hard drives to solid-state drives continues across enterprise deployments, and the company's reputation for bulletproof performance has made it a preferred vendor for operators who can't afford failure.
That brand equity is doing real work in a market where procurement decisions are increasingly driven by reliability track records, not just spec sheets.
Revenue and earnings growth have been strong, and Seagate scores well on his fundamental model, though at a higher multiple than Micron. That premium doesn't concern him. Storage has historically demanded a higher valuation than DRAM, and Seagate's market share position and switching costs justify the spread. His posture: ride it as long as the fundamentals hold.
Western Digital and Sandisk: Strong Names, Slightly Lower Scores
Western Digital and Sandisk both have meaningful exposure to the same AI storage surge. Navellier is careful not to dismiss either—comparing them unfavorably to Micron and Seagate, he says, is like being asked to pick a favorite child.
If pressed, he leans toward Sandisk over Western Digital on the basis of analyst revision momentum, earnings surprise history, and margin expansion trajectory. But both names score well on his model; they simply score below the top two. The demand environment is strong enough that all four can win simultaneously—the distinction comes down to who captures the most orders when speed and reliability are the deciding factors.
How to Think About Entry After a Monster Run
All four stocks have posted extraordinary gains. That makes entry feel uncomfortable, and Navellier acknowledges it. His approach: put them on an alert list and buy into daily pullbacks rather than chasing strength. The memory sector's natural oscillation means stocks that run 12% will typically give back 3% to 4% before the next leg—and those brief windows are where he builds or adds positions.
For investors already in these names, the calculus is different. Navellier's rule for his own portfolio is simple: if a stock still scores well on fundamentals—strong sales, expanding margins, positive revisions, solid surprise history—the size of the gain isn't a reason to sell. The stocks that have run 100%, 500%, or more in his portfolio are still there because the underlying businesses haven't deteriorated. The gain is a feature, not a warning sign.
The broader backdrop supports staying engaged. Data center construction is ongoing, AI compute demand continues growing, and the memory shortage driving Apple's pricing warning isn't a quarterly blip. The bottleneck that's making iPhones more expensive is the same bottleneck that's making these four stocks very difficult to bet against.
MarketBeat empowers everyday investors to make better investment decisions by offering real-time financial information and unbiased market research.
If you have questions about your account, please contact MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Suite 620, Sioux Falls, SD 57103-7078. USA..